Integrating Molecular Pathology Into NSCLC Treatment Selection
Ignacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer.
Ignacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer (NSCLC).
There have been advances in molecular detection, particularly with identification of driver mutations and fusions, Wistuba explains. The clinical pathology community has also tried to minimize the use of tissue for analyses. However, there are challenges, he adds, because molecular testing is still not yet widespread. Moreover, liquid biopsy is an emerging field for pathologists, especially in lung cancer.
